Nuvilex Inc., of Silver Spring, Md., said partner Astrianova Singapore Pte Ltd., of Singapore, reported results from the second phase II trial combining the Cell-in-a-Box cellulose-based live cell encapsulation technology plus low doses of cancer prodrug ifosfamide in patients with advanced, inoperable cancer.